Definitive Contract HHSN272201500015C
- Not listed
- This is a $12,664.08 firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to the Texas Biomedical Research Institute, doing business as Southwest Foundation For Biomedical Research. The contract is for research services to assay the effect of drug and control on Ebola virus infection of cells under biosafety level 4 conditions, including collecting supernatants and measuring...
- This is a $544,000.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is for biomedical (applied/exploratory) research and does not have a set-aside designation. Through this contract, Southern Research Institute is providing a range of services, including drug discovery and...
- This contract was awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to SRI International, a non-profit research institute, to provide preclinical services for the development of Ebola therapeutics. The $3,523,511 base award has a potential value of $7,727,328.00. The contract is a Delivery Order under the Major Program Code "PRECLINICAL SERVICES FOR THE DEVELOPMENT OF INTERVENTIONAL AGENTS FOR...
- This is a $4,722,966.14 firm fixed-price definitive contract awarded by the Joint PEO Chemical and Biological Defense to the Texas Biomedical Research Institute, doing business as the Southwest Foundation For Biomedical Research. The contract, which does not have a set-aside designation, supports the development and refinement of animal and animal replacement models for evaluating candidate countermeasures against infectious agents with pandemic potential. The institute operates the Southwest...
- This is a $11,971,183.00 federal contract award from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to the Texas Biomedical Research Institute (TBRI), a non-profit research organization. The contract is for "GLP NATURAL HISTORY STUDIES IN NHP MODELS OF FILOVIRUS INFECTION" and has a period of performance through June 1, 2026. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type. It does not have a set-aside...
- The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $208,600.00 firm-fixed-price delivery order contract to Southern Research Institute to conduct "EBOLA, ENTEROVIRUS-68 AND ENTEROVIRUS SCREENS". This award is part of the larger "In Vitro Antimicrobial Assessments 2011-2018" indefinite delivery/indefinite quantity (IDIQ) contract. Southern Research Institute is a corporate entity tax-exempt non-profit organization that provides...
- This federal contract award, valued at $73,343,960.25, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc. The contract supports research on the Ebola virus and other infectious diseases. The scope of work includes but is not limited to strategic and operational planning, infrastructure operations and maintenance, logistics and procurement management, clinical research protocol...
- This is a definitive, labor-hour contract awarded by the Department of Health and Human Services (HHS) to the Texas Biomedical Research Institute, doing business as the Southwest Foundation for Biomedical Research. The $13,597,494 contract supports various research and development efforts across areas like infectious diseases, including filoviruses, HIV/AIDS, and COVID-19. The institute frequently partners with other entities on these contracts and receives substantial federal grant funding,...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Emory University. The $3,458,502.19 cost-no-fee contract is for "TARGETING THERAPEUTICS DEVELOPMENT TO RELIEVE BOTTLENECKS: OPTIMIZONG LEAD THERAPEUTIC COMPOUNDS AGAINST INFECTIOUS PATHOGENS." It has a period of performance through October 31, 2018. The contract is not designated as a set-aside. The contract has several...
- This is a federal contract award to Southern Research Institute, a non-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Department of Health and Human Services (HHS). The contract has a ceiling value of $26,986,655.00 and was awarded on September 15, 2003 with a period of performance through September 29, 2010. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type. Southern Research Institute, also known as Southern...
This is a $3,880,651.60 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Southwest Research Institute (SwRI) to optimize lead therapeutic compounds against infectious pathogens. The contract is not set aside. SwRI, a nonprofit research organization, will conduct research and development activities to help relieve bottlenecks in the development of targeted therapeutics. The contract includes three subcontracts. The University of Texas Medical Branch at Galveston (UTMB) will conduct guinea pig studies to assess the tolerance, minimal effective dose, and post-exposure treatment of test articles provided by SwRI against the Ebola virus. Citoxlab Amerique du Nord Inc. and Alturas Analytics Inc. will provide additional preclinical research and analytical services supporting the contract efforts. This contract appears to be part of NIAID's broader program focused on advancing the development of new medical countermeasures against infectious diseases. SwRI's expertise in areas like defense systems and biomedical research makes it well-positioned to support this work on behalf of the government.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Targeting Therapeutics Development to Relieve Bottlenecks | BAA-NIAID-DMID-NIH-AI-2014007 | Department of Health and Human Services National Institutes of Health | Award Notice 1/1 | 6/13/14, 11:50 AM |
ContractNumber | Description | Subcontractor | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
M99004JWS | University Of Texas Medical Branch At Galveston | Definitive Contract HHSN272201500015C | $455.0k | 12/19/18 | |
J77363JWS | Citoxlab Amerique DU Nord Inc. | Definitive Contract HHSN272201500015C | $77.5k | 12/18/17 | |
L77362JWS | Alturas Analytics Inc. | Definitive Contract HHSN272201500015C | $52.0k | 12/6/17 |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00010 | Close Out | ($559k) | 10/26/20 | |
| P00009 | Other Administrative Action | $0 | 11/8/18 | |
| 8 | Supplemental Agreement for work within scope | $54.2k | 9/18/18 | |
| 7 | Supplemental Agreement for work within scope | $287.7k | 7/5/18 | |
| 6 | Supplemental Agreement for work within scope | $0 | 1/23/18 |